Each vial contains: amoxicillin (as sodium amoxicillin) 500mg, sulbactam (as sulbactam sodium) 250mg.
Each ampoule contains: 5ml sterile distilled water.
Trifamox IBL is specifically recommended for the treatment of infections due to microorganisms resistant to betalactamic and cephalosporinic antibiotic single therapy, due to their betalacatmase producing capacity.
It is recommended that adequate microbiological tests (cultures and susceptibility tests) be performed before treatment start in order to identify the microorganisms that cause the infection and determine their susceptibility to Trifamox IBL.
Treatment can be started before the results of bacterial tests become available when there re reasons to believe that betalactamase producing organisms are involved as etiological agents. Once the results are available, the treatment
can be modified, if necessary.
When administered at the recommended dosage, the drug is generally well-tolerated. Some patients may develop untoward reactions of different types and severity. The following adverse reactions have been reported:
Gastrointestinal disorders: nausea, vomiting, diarrhea, dyspepsia and epigastralgia
Hypersensitivity reactions: urticaria, Quincke’s edema, skin maculopapular rash and rarely, anaphylactic shock.
Interstitial nephritis
Hematologic reactions: neutropenia, eosinophilia, anemia and platelet dysfunction
Oral candidiasis – or other areas – as an expression of normal flora alteration
Exceptionally, Stevens-Johnson syndrome and erythema multiforme
Cases of pseudomembranous colitis have been reported with the use of aminopenicillins.
Each vial contains: amoxicillin (as sodium amoxicillin) 1.000mg, sulbactam (as sulbactam sodium) 500mg.
Each ampoule contains: 5ml sterile distilled water.
Trifamox IBL is specifically recommended for the treatment of infections due to microorganisms resistant to betalactamic and cephalosporinic antibiotic single therapy, due to their betalacatmase producing capacity.
It is recommended that adequate microbiological tests (cultures and susceptibility tests) be performed before treatment start in order to identify the microorganisms that cause the infection and determine their susceptibility to Trifamox IBL.
Treatment can be started before the results of bacterial tests become available when there re reasons to believe that betalactamase producing organisms are involved as etiological agents. Once the results are available, the treatment
can be modified, if necessary.
When administered at the recommended dosage, the drug is generally well-tolerated. Some patients may develop untoward reactions of different types and severity. The following adverse reactions have been reported:
Gastrointestinal disorders: nausea, vomiting, diarrhea, dyspepsia and epigastralgia
Hypersensitivity reactions: urticaria, Quincke’s edema, skin maculopapular rash and rarely, anaphylactic shock.
Interstitial nephritis
Hematologic reactions: neutropenia, eosinophilia, anemia and platelet dysfunction
Oral candidiasis – or other areas – as an expression of normal flora alteration
Exceptionally, Stevens-Johnson syndrome and erythema multiforme
Cases of pseudomembranous colitis have been reported with the use of aminopenicillins.
Each Film – Coated Tablet contains:
Amoxicillin (as Amoxicillin Trihydrate) 250 mg; Sulbactam (as Pivsulbactam) 250 mg
Excipients: Croscarmellose Sodium; Magnesium Stearate; Colloidal Anhydrous Silica; Lactose, Hypromellose; Titanium Dioxide; Triacetin; Yellow 10 Ferric Oxide; Microcrystalline Cellulose
Trifamox IBL is specifically recommended for the treatment of infections due to microorganisms resistant to betalactamic and cephalosporinic antibiotic single therapy, due to their betalacatmase producing capacity.
It is recommended that adequate microbiological tests (cultures and susceptibility tests) be performed before treatment start in order to identify the microorganisms that cause the infection and determine their susceptibility to Trifamox IBL.
Treatment can be started before the results of bacterial tests become available when there re reasons to believe that betalactamase producing organisms are involved as etiological agents. Once the results are available, the treatment
can be modified, if necessary.
When administered at the recommended dosage, the drug is generally well-tolerated. Some patients may develop untoward reactions of different types and severity. The following adverse reactions have been reported:
Gastrointestinal disorders: nausea, vomiting, diarrhea, dyspepsia and epigastralgia
Hypersensitivity reactions: urticaria, Quincke’s edema, skin maculopapular rash and rarely, anaphylactic shock.
Interstitial nephritis
Hematologic reactions: neutropenia, eosinophilia, anemia and platelet dysfunction
Oral candidiasis – or other areas – as an expression of normal flora alteration
Exceptionally, Stevens-Johnson syndrome and erythema multiforme
Cases of pseudomembranous colitis have been reported with the use of aminopenicillins.
Each tablet contains clarithromycin 250 mg / 500 mg
H-pylori infection
Tonsillitis / Pharyngitis, AECB, Pneumonia and uncomplicated skin and soft tissue infections
The most frequently reported side effects include diarrhea, nausea, abnormal taste, dyspepsia, abdominal pain / discomfort and headache. The post marketing experience has attributed some allergic side effects to clarithromycin, ranging from urticaria to rare anaphylaxis
Each film coated Tablet contains levofloxacin (as hemihydrate): 200mg /500 mg
Levo is indicated for the treatment of mild, moderate, and severe infections caused by susceptible strains of the designated microorganisms in the conditions listed below.
Acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis
Complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coil, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa
Uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus
The following events were considered likely to be drug-related in patients receiving levofloxacin
nausea, diarrhea, vaginitis, insomnia, abdominal pain, flatulence, pruritus , dizziness , rash, dyspepsia , genital moniliasis, moniliasis, taste perversion, vomiting , constipation, fungal infection , genital pruritis, headache , nervousness , rash erythematous , urticaria , anorexia , somnolence, agitation, rash maculo-papular, dry mouth , tremor, condition aggravated, allergic reaction.
Eleva Plus Injection 1 gm Each vial contains:
Cefoperazone (Sodium) U.S.P. . 0.5gm
Sulbactam (Sodium) U.S.P 0.5gm
Eleva Plus Injection 2gm
Each vial contains:
Cefoperazone (Sodium) U.S.P. 1gm
Sulbactam (Sodium) U.S.P. 1gm
Mono-Therapy
Sulbactam/Cefoperazone (Eleva Plus) is indicated for the treatment of the following infections when caused by susceptible organisms: Respiratory Tract infections (Upper and Lower), Urinary Tract Infections, Peritonitis, Cholecystitis, Cholangitis, and other intra-Abdominal Infections, Septicemia, Meningitis, Skin and Soft Tissue infections, Bone and Joint Infections, Pelvic Inflammatory Disease, Endometritis, Gonorrhea, and Other Infections of the Genital Tract.
Combination Therapy
Because of the broad spectrum of activity of Sulbactam/Cefoperazone (Eleva Plus), most infections can be treated adequately with this antibiotic alone. However, Sulbactam/Cefoperazone may be used concomitantly with other antibiotics if such combinations are indicated. If an aminoglycoside is used renal function should be monitored during the course of therapy.
Sulbactam/Cefoperazone (Eleva Plus) is generally well-tolerated. The majority of adverse events are of mild or moderate severity are tolerated with continued treatment. The most frequent side effects observed with Sulbactam/Cefoperazone (Eleva Plus) are gastrointestinal. Others include dermatologic reactions, headache, injection pain, chills and anaphylactoid reactions.
Each film coated Tablet contains azithromycin USP
(as azithromycin dihydrate USP) 250/500mg
Excipients q.s
Azeath is indicated for the following bacterial infection induced by microorganisms susceptible to azithromycin
Very common: Diarrhoea
Common: Changes in the numbers of some white blood cells and blood bicarbonate Headache Vomiting, stomach pain, feeling sick
Uncommon: Allergic reactions, Loss of appetite. Sight disorders, Ear disorders, Hot flush. Difficulty breathing, Chest pain, swelling, feeling unwell, weakness, tiredness
Rare: Agitation, Abnormal liver function, jaundice, Reddening and blistering of the skin when exposed to sunlight
Flucloxacillin Sodium BP
Excipients q s.
Treatment of infections due to sensitive Gram-positive organisms. including infections caused by beta-lactamase-producing Staphylococci, Streptococci.Flucloxacillin is also indicated for use as a prophylactic during major surgical procedures such as cardiothoracic and orthopedic surgery.
The following convention has been utilized for the classification of undesirable effects: Blood and lymphatic system disorders, Immune system disorders, Gastrointestinal disorders, Hepato-biliary disorders, Skin and subcutaneous tissue disorders, Musculoskeletal and connective tissue disorders, Renal and urinary disorders.
Erythromycin Stearate USP
Excipients q.s.
Erythromycin is used for the prophylaxis and treatment of infections caused by erythromycin-sensitive organisms.
Erythromycin is highly effective in the treatment of a great variety of clinical infections such as:
Upper Respiratory Tract infections: tonsillitis, peritonsillar abscess, pharyngitis, laryngitis, sinusitis, secondary infections in influenza and common colds
Lower Respiratory Tract infections: tracheitis, acute and chronic bronchitis, pneumonia (lobar pneumonia, bronchopneumonia, primary atypical pneumonia), bronchiectasis, Legionnaire’s disease
Ear infection: otitis media and otitis externa, mastoiditis
Oral infections: gingivitis, Vincent’s angina
Eye infections: blepharitis
Skin and soft tissue infections: boils and carbuncles, paronychia, abscesses, pustular acne, impetigo, cellulitis, erysipelas
Gastrointestinal infections: cholecystitis, staphylococcal enterocolitis
Prophylaxis: pre- and post- operative trauma, burns, rheumatic fever
Other infections: osteomyelitis, urethritis, gonorrhea, syphilis, lymphogranuloma venereum, diphtheria, prostatitis, scarlet fever.
Blood and lymphatic system disorders:
Eosinophilia.
Cardiac disorders
QTc interval prolongation, torsades de pointes, palpitations, and cardiac rhythm disorders including ventricular tachyarrhythmias.
Ear and labyrinth disorders
Deafness, tinnitus
There have been isolated reports of reversible hearing loss occurring chiefly in patients with renal insufficiency or high doses.
Gastrointestinal disorders
The most frequent side effects of oral erythromycin preparations are gastrointestinal and are dose-related. The following have been reported:
upper abdominal discomfort, nausea, vomiting, diarrhea, pancreatitis, anorexia, infantile hypertrophic pyloric stenosis.
Pseudomembranous colitis has been rarely reported in association with erythromycin therapy.
General disorders and administration site conditions
Chest pain, fever, malaise.
Hepatobiliary disorders
Cholestatic hepatitis, jaundice, hepatic disfunction, hepatomegaly, hepatic failure, hepatocellular hepatitis.
Immune system disorders
Allergic reactions
Investigations
Increased liver enzyme values
Nervous system disorders
There have been isolated reports of transient central nervous system side effects including confusion, seizures and vertigo; however, a cause and effect relationship has not been established.
Psychiatric disorders, Hallucinations, Renal and urinary disorders, Interstitial nephritis, Skin and subcutaneous tissue disorders,
Skin eruptions, pruritus, urticaria, exanthema, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme.
Vascular disorders, Hypotension.
ZEEKAN 200mg/5ml Suspension
Each 5ml contains:
Azithromycin (as Dihydrate) U.S.P. 200mg
Azithromycin (ZEEKAN) is active against both Gram-positive and Gram-negative organisms. It is indicated for the treatment of infections caused by susceptible bacteria in conditions listed below:
Upper Respiratory Tract Infection: Acute Pharyngitis, Acute Tonsillitis, Sinusitis and Acute Otitis media.
Lower Respiratory Tract Infections: Acute bronchitis, Acute bacterial exacerbations of Chronic Obstructive Pulmonary Disease (COPD) and Pneumonia.
Uncomplicated Skin and Skin Structure Infections: Due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage.
Genitourinary Infections: Infections due to Chlamydia trachomatis like Nongonococcal
Urethritis and Cervicitis.
Azithromycin (ZEEKAN) is well tolerated with a low incidence of side effects. Majority of the side effects were mild to moderate in nature and of gastrointestinal in origin with nausea, abdominal discomfort, vomiting, flatulence and diarrhea. Allergic reactions such as rash have occurred and there have also been rare reports of serious hypersensitivity reactions. Reversible elevations in liver transaminases have been seen with a frequency similar to the comparative Macrolides and Penicillins used in clinical trials. Transient mild reductions in neutrophil counts have occasionally been observed in clinical trials, although a causal relationship to Azithromycin (ZEEKAN) has not been established.
